Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003123440 | SCV003800958 | pathogenic | Qualitative or quantitative defects of dystrophin | 2023-01-03 | criteria provided, single submitter | clinical testing | Variant summary: The variant identified by MLPA or other technology involves the deletion of exons 3-6 in the DMD gene. A presumed nomenclature of c.(93+1_94-1)_(530+1_531-1)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is expected to result in a frameshift in the DMD gene, a known mechanism of disease. The variant was absent in 16104 control chromosomes (gnomAD, Structural Variants dataset). Deletion of exons 3-6 has been reported in the literature in multiple individuals affected with Dystrophinopathies (e.g. Moizard_1998, Taylor_2007, Ling_2020). These data indicate that the variant is very likely to be associated with disease. A ClinVar submitter (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |